asx ann april 30

BDM 10:21 AM BioDiem completes recruitment of patients for clinical trial
http://www.asx.com.au/asxpdf/20070430/pdf/3125py0kj04v57.pdf

BioDiem completes recruitment of patients for its clinical trial in
diabetic eye disease
Australian biopharmaceutical development company BioDiem Ltd (ASX:BDM)
announced today it has completed recruitment of 192 patients in a phase I/II clinical trial of its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.

Commenting on this milestone today, BioDiem Chief Executive Officer, Tom Williams said, “It’s pleasing to have completed this significant step in executing the clinical trial. We now expect to report on the result of the trial during Q4, CY 2007.”